- Home
- IMVT
IMVT
Immunovant Inc.
as 05-30-2025 4:00pm EST
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 2.5B | IPO Year: | N/A |
| Target Price: | $40.14 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.72 - $34.47 | Next Earning Date: | 05-29-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 108.88% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Immunovant Inc. (IMVT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Geffner Michael | IMVT | Chief Medical Officer | Apr 23 '25 | Sell | $14.79 | 2,349 | $34,741.71 | 225,370 | |
| Stout Jay S | IMVT | Chief Technology Officer | Apr 23 '25 | Sell | $14.79 | 1,925 | $28,470.75 | 209,243 | |
| Barnett Eva Renee | IMVT | Chief Financial Officer | Apr 16 '25 | Sell | $14.89 | 2,993 | $44,565.77 | 396,774 | |
| Salzmann Peter | IMVT | Chief Executive Officer | Apr 16 '25 | Sell | $14.89 | 8,321 | $123,899.69 | 1,178,191 | |
| Barnett Eva Renee | IMVT | Chief Financial Officer | Apr 9 '25 | Sell | $12.99 | 11,063 | $143,708.37 | 396,774 | |
| Salzmann Peter | IMVT | Chief Executive Officer | Apr 9 '25 | Sell | $12.99 | 28,094 | $364,941.06 | 1,178,191 | |
| Geffner Michael | IMVT | Chief Medical Officer | Apr 9 '25 | Sell | $12.99 | 6,169 | $80,135.31 | 225,370 | |
| Stout Jay S | IMVT | Chief Technology Officer | Apr 9 '25 | Sell | $12.99 | 5,004 | $65,001.96 | 209,243 | |
| Fromkin Andrew J. | IMVT | Director | Mar 7 '25 | Sell | $19.74 | 8,000 | $156,768.96 | 91,913 |
Latest Immunovant Inc. News
IMVT Breaking Stock News: Dive into IMVT Ticker-Specific Updates for Smart Investing
Zacks
a day ago
IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus
MT Newswires
3 days ago
Immunovant's Fiscal Q4 Net Loss Widens
GlobeNewswire
3 days ago
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025
Insider Monkey
3 days ago
H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock
Insider Monkey
22 days ago
Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back?
MT Newswires
a month ago
UBS Downgrades Immunovant to Neutral, Price Target is $17
BioPharma Dive
a month ago
Akeso claims another PD-1/VEGF win; FDA requests more data from Novavax
Investor's Business Daily
a month ago
Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug
Compare IMVT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMVT Immunovant Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.